Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease

Guochun Chen, Huihui Chen, Shuyu Ren, Ming Xia, Jiefu Zhu, Yu Liu, Lei Zhang, Luosheng Tang, Lin Sun, Hong Liu, Zheng Dong

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

DNA methylation has been implicated in the pathogenesis of diabetic kidney disease (DKD), but the underlying mechanisms remain unclear. In this study, we tested the hypothesis that aberrant DNA methylation in peripheral immune cells contributes to DKD progression. We showed that levels of DNA methyltransferase 1 (DNMT1), a key enzyme for DNA methylation, were increased along with inflammatory activity of peripheral blood mononuclear cells in DKD patients. Inhibition of DNMT1 with 5-aza-2'-deoxycytidine (5-Aza) markedly increased the proportion of CD4+CD25+ regulatory T cells in peripheral blood mononuclear cells in culture and in diabetic animals. Adoptive transfer of immune cells from 5-Aza-treated animals showed beneficial effects on the host immune system, resulting in a significant improvement of DKD. Using genome-wide DNA methylation assays, we identified the differentially methylated cytosines in the promoter regions of mammalian target of rapamycin (mTOR) regulators in peripheral blood mononuclear cells of diabetic patients. Further, mRNA arrays confirmed the consistent induction of genes expressed in the mTOR pathway. Importantly, down-regulation of DNMT1 expression via RNA interference resulted in prominent cytosine demethylation of mTOR negative regulators and subsequent decrease of mTOR activity. Lastly, modulation of mTOR resulted in changes in the effect of 5-aza on diabetic immune cells. Thus, up-regulation of DNMT1 in diabetic immune cells induces aberrant cytosine methylation of the upstream regulators of mTOR, leading to pathogenic activation of the mTOR pathway and consequent inflammation in diabetic kidneys. Hence, this study highlights therapeutic potential of targeting epigenetic events in immune system for treating DKD.

Original languageEnglish (US)
Pages (from-to)409-420
Number of pages12
JournalKidney International
Volume96
Issue number2
DOIs
StatePublished - Aug 1 2019

Fingerprint

Diabetic Nephropathies
DNA Methylation
Sirolimus
Methyltransferases
Cytosine
Genes
Blood Cells
DNA
decitabine
Immune System
Adoptive Transfer
Regulatory T-Lymphocytes
RNA Interference
Genetic Promoter Regions
Epigenomics
Methylation
Disease Progression
Up-Regulation
Down-Regulation
Cell Culture Techniques

Keywords

  • DNA methylation
  • DNA methyltransferase 1
  • chronic inflammation
  • diabetic kidney disease
  • mammalian target of rapamycin

ASJC Scopus subject areas

  • Nephrology

Cite this

Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease. / Chen, Guochun; Chen, Huihui; Ren, Shuyu; Xia, Ming; Zhu, Jiefu; Liu, Yu; Zhang, Lei; Tang, Luosheng; Sun, Lin; Liu, Hong; Dong, Zheng.

In: Kidney International, Vol. 96, No. 2, 01.08.2019, p. 409-420.

Research output: Contribution to journalArticle

Chen, Guochun ; Chen, Huihui ; Ren, Shuyu ; Xia, Ming ; Zhu, Jiefu ; Liu, Yu ; Zhang, Lei ; Tang, Luosheng ; Sun, Lin ; Liu, Hong ; Dong, Zheng. / Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease. In: Kidney International. 2019 ; Vol. 96, No. 2. pp. 409-420.
@article{5e50745519e740029e62ccda06f95bb4,
title = "Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease",
abstract = "DNA methylation has been implicated in the pathogenesis of diabetic kidney disease (DKD), but the underlying mechanisms remain unclear. In this study, we tested the hypothesis that aberrant DNA methylation in peripheral immune cells contributes to DKD progression. We showed that levels of DNA methyltransferase 1 (DNMT1), a key enzyme for DNA methylation, were increased along with inflammatory activity of peripheral blood mononuclear cells in DKD patients. Inhibition of DNMT1 with 5-aza-2'-deoxycytidine (5-Aza) markedly increased the proportion of CD4+CD25+ regulatory T cells in peripheral blood mononuclear cells in culture and in diabetic animals. Adoptive transfer of immune cells from 5-Aza-treated animals showed beneficial effects on the host immune system, resulting in a significant improvement of DKD. Using genome-wide DNA methylation assays, we identified the differentially methylated cytosines in the promoter regions of mammalian target of rapamycin (mTOR) regulators in peripheral blood mononuclear cells of diabetic patients. Further, mRNA arrays confirmed the consistent induction of genes expressed in the mTOR pathway. Importantly, down-regulation of DNMT1 expression via RNA interference resulted in prominent cytosine demethylation of mTOR negative regulators and subsequent decrease of mTOR activity. Lastly, modulation of mTOR resulted in changes in the effect of 5-aza on diabetic immune cells. Thus, up-regulation of DNMT1 in diabetic immune cells induces aberrant cytosine methylation of the upstream regulators of mTOR, leading to pathogenic activation of the mTOR pathway and consequent inflammation in diabetic kidneys. Hence, this study highlights therapeutic potential of targeting epigenetic events in immune system for treating DKD.",
keywords = "DNA methylation, DNA methyltransferase 1, chronic inflammation, diabetic kidney disease, mammalian target of rapamycin",
author = "Guochun Chen and Huihui Chen and Shuyu Ren and Ming Xia and Jiefu Zhu and Yu Liu and Lei Zhang and Luosheng Tang and Lin Sun and Hong Liu and Zheng Dong",
year = "2019",
month = "8",
day = "1",
doi = "10.1016/j.kint.2019.02.020",
language = "English (US)",
volume = "96",
pages = "409--420",
journal = "Kidney International",
issn = "0085-2538",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Aberrant DNA methylation of mTOR pathway genes promotes inflammatory activation of immune cells in diabetic kidney disease

AU - Chen, Guochun

AU - Chen, Huihui

AU - Ren, Shuyu

AU - Xia, Ming

AU - Zhu, Jiefu

AU - Liu, Yu

AU - Zhang, Lei

AU - Tang, Luosheng

AU - Sun, Lin

AU - Liu, Hong

AU - Dong, Zheng

PY - 2019/8/1

Y1 - 2019/8/1

N2 - DNA methylation has been implicated in the pathogenesis of diabetic kidney disease (DKD), but the underlying mechanisms remain unclear. In this study, we tested the hypothesis that aberrant DNA methylation in peripheral immune cells contributes to DKD progression. We showed that levels of DNA methyltransferase 1 (DNMT1), a key enzyme for DNA methylation, were increased along with inflammatory activity of peripheral blood mononuclear cells in DKD patients. Inhibition of DNMT1 with 5-aza-2'-deoxycytidine (5-Aza) markedly increased the proportion of CD4+CD25+ regulatory T cells in peripheral blood mononuclear cells in culture and in diabetic animals. Adoptive transfer of immune cells from 5-Aza-treated animals showed beneficial effects on the host immune system, resulting in a significant improvement of DKD. Using genome-wide DNA methylation assays, we identified the differentially methylated cytosines in the promoter regions of mammalian target of rapamycin (mTOR) regulators in peripheral blood mononuclear cells of diabetic patients. Further, mRNA arrays confirmed the consistent induction of genes expressed in the mTOR pathway. Importantly, down-regulation of DNMT1 expression via RNA interference resulted in prominent cytosine demethylation of mTOR negative regulators and subsequent decrease of mTOR activity. Lastly, modulation of mTOR resulted in changes in the effect of 5-aza on diabetic immune cells. Thus, up-regulation of DNMT1 in diabetic immune cells induces aberrant cytosine methylation of the upstream regulators of mTOR, leading to pathogenic activation of the mTOR pathway and consequent inflammation in diabetic kidneys. Hence, this study highlights therapeutic potential of targeting epigenetic events in immune system for treating DKD.

AB - DNA methylation has been implicated in the pathogenesis of diabetic kidney disease (DKD), but the underlying mechanisms remain unclear. In this study, we tested the hypothesis that aberrant DNA methylation in peripheral immune cells contributes to DKD progression. We showed that levels of DNA methyltransferase 1 (DNMT1), a key enzyme for DNA methylation, were increased along with inflammatory activity of peripheral blood mononuclear cells in DKD patients. Inhibition of DNMT1 with 5-aza-2'-deoxycytidine (5-Aza) markedly increased the proportion of CD4+CD25+ regulatory T cells in peripheral blood mononuclear cells in culture and in diabetic animals. Adoptive transfer of immune cells from 5-Aza-treated animals showed beneficial effects on the host immune system, resulting in a significant improvement of DKD. Using genome-wide DNA methylation assays, we identified the differentially methylated cytosines in the promoter regions of mammalian target of rapamycin (mTOR) regulators in peripheral blood mononuclear cells of diabetic patients. Further, mRNA arrays confirmed the consistent induction of genes expressed in the mTOR pathway. Importantly, down-regulation of DNMT1 expression via RNA interference resulted in prominent cytosine demethylation of mTOR negative regulators and subsequent decrease of mTOR activity. Lastly, modulation of mTOR resulted in changes in the effect of 5-aza on diabetic immune cells. Thus, up-regulation of DNMT1 in diabetic immune cells induces aberrant cytosine methylation of the upstream regulators of mTOR, leading to pathogenic activation of the mTOR pathway and consequent inflammation in diabetic kidneys. Hence, this study highlights therapeutic potential of targeting epigenetic events in immune system for treating DKD.

KW - DNA methylation

KW - DNA methyltransferase 1

KW - chronic inflammation

KW - diabetic kidney disease

KW - mammalian target of rapamycin

UR - http://www.scopus.com/inward/record.url?scp=85065506522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065506522&partnerID=8YFLogxK

U2 - 10.1016/j.kint.2019.02.020

DO - 10.1016/j.kint.2019.02.020

M3 - Article

VL - 96

SP - 409

EP - 420

JO - Kidney International

JF - Kidney International

SN - 0085-2538

IS - 2

ER -